Transaction DateRecipientSharesTypePriceValue
22nd February 2021Bernie B Iii Berry1,600Open or private sale$57.09$91,344.00
19th February 2021Bernie B Iii Berry1,701Open or private sale$57.16$97,229.16
19th February 2021Gregory A Odle3,750Open or private sale$56.50$211,875.00
18th February 2021Bernie B Iii Berry4,000Open or private sale$54.07$216,280.00
5th February 2021Mark C Throdahl12,651Open or private sale$50.34$636,851.34
4th February 2021Mark C Throdahl7,349Open or private sale$50.18$368,772.82
27th January 2021Gregory A Odle3,750Open or private sale$51.63$193,612.50
27th January 2021Bernie B Iii Berry3,136Open or private sale$51.73$162,225.28
23rd December 2020Gregory A Odle3,750Open or private sale$46.19$173,212.50
18th December 2020David R Pelizzon1,350,135Grant/award etc.$11.11$14,999,999.85
Ortho Pediatrics
Ortho Pediatrics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


OrthoPediatrics Corp. is a medical device company. Its products includes PediLoc, PediPlates, Cannulated Screws and PediFlexTM nail.


Ticker: KIDS
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1425450
Employees: 94
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $113 M (59%)
Inventory, Net: $49 M (28%)
Assets, Current: $180 M (40%)
Property, Plant and Equipment, Net: $24 M (13%)
Assets: $328 M (80%)
Long-term Debt, Current Maturities: $128 Th (3%)
Accounts Payable, Current: $6 M (-7%)
Liabilities, Current: $25 M (81%)
Long-term Debt, Excluding Current Maturities: $21 M (-19%)
Other Liabilities, Noncurrent: $120 Th (90%)
Liabilities: $86 M (116%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $20 M (16%)
Retained Earnings (Accumulated Deficit): $143 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $161 Th (5266%)
Stockholders' Equity (Parent): $242 M (0%)
Liabilities and Equity: $328 M (80%)
Revenue: $14 M (0%)
Cost of Revenue: $4 M (-53%)
Gross Margin: $10 M (-54%)
Research and Development: $881 Th (-58%)
Sales and Marketing: $6 M (-57%)
General and Administrative Expenses: $11 M (-42%)
Operating Income/Loss: $7 M (-39%)
Other Income, net: $2 M (-15%)